Amitiza lubiprostone: Completed Phase III enrollment

Sucampo completed enrollment of 209 patients in an open-label, Japanese Phase III safety trial evaluating 24 µg of oral lubiprostone given twice daily for up to 48 weeks. Abbott has exclusive rights t...